Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 12/20 | 0.37 |
| ▸ | DPP4 | P27487 | 7/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922467 | 0.86 | DPP4 (0.42) | CRHR1DPP4DPP8CYP3A4CYP2C9 | |
| SCHEMBL1922662 | 0.84 | DPP4 (0.41) | CRHR1DPP4DPP8CYP3A4CYP2C9 | |
| SCHEMBL2258055 | 0.82 | PTGS1 (0.39) | CRHR1DPP4DPP8MAPT | |
| SCHEMBL1922037 | 0.81 | DPP4 (0.45) | DPP4DPP8POLBMAPT | |
| SCHEMBL1922525 | 0.79 | DPP4 (0.44) | CRHR1DPP4DPP8 | |
| SCHEMBL1923091 | 0.79 | DPP4 (0.39) | CRHR1DPP4DPP8MAPTCYP3A4 | |
| SCHEMBL1922300 | 0.77 | DPP4 (0.42) | CRHR1DPP4DPP8CYP3A4CYP2C9 | |
| SCHEMBL1922556 | 0.76 | DPP4 (0.40) | CRHR1DPP4DPP8 | |
| SCHEMBL1922331 | 0.76 | DPP4 (0.35) | CRHR1DPP4DPP8 | |
| SCHEMBL2256801 | 0.76 | DPP4 (0.39) | CRHR1DPP4DPP8CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011529943-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | claimed |
| EP-2328902-A1 | PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | Novartis AG (CH) | 2011-06-08 | — | — | EP | claimed |
| WO-2010015628-A1 | PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | claimed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | claimed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-2328902-A1 | PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | Novartis AG (CH) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010015628-A1 | PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015628-A1 | PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035874-A1 | Organic compounds | CRH, CRHR1, CRHR2 | CRHR1 2/4885DPP4 958/4885DPP8 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.